Zymeworks开始为ZW191试验第1阶段,一种针对显示FR-α的先进固态肿瘤的药物。 Zymeworks begins Phase 1 trial for ZW191, a drug targeting advanced solid tumors expressing FR-α.

Zymeworks已经启动了其药物ZW191的第一阶段临床试验,其目的是治疗表现叶酸受体α(FR-α)的先进固态肿瘤,如卵巢癌和肺癌。 Zymeworks has initiated a Phase 1 clinical trial for its drug ZW191, which aims to treat advanced solid tumors that express the folate receptor-α (FR-α), such as ovarian and lung cancers. 该试验涉及145名成人病人,将评估该药物的安全性、可耐性和潜在效力。 The trial, involving 145 adult patients, will assess the drug's safety, tolerability, and potential effectiveness. ZW191设计成一种抗体药物合体,针对FR-α,向癌症细胞直接提供细胞毒剂,标志着Zymework公司迈出的重要一步。 ZW191 is designed as an antibody-drug conjugate that targets FR-α to deliver a cytotoxic agent directly to cancer cells, marking a significant step for Zymeworks.